Cerevel Therapeutics announced positive results from a Phase 3 trial of its Parkinson's disease drug, tavapadon, which showed improved motor symptom control when used as an adjunct therapy with levodopa. The trial's success comes ahead of a planned acquisition of Cerevel by AbbVie. Tavapadon works by partially activating the D1 and D5 dopamine receptors, aiming to achieve optimal dopamine signaling without overstimulating the D2 and D3 receptors.
Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study https://t.co/i5Tmcv6pbE $CERE by @NedPagliarulo
Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study $CERE #neuroscience #biotech via @NedPagliarulo https://t.co/Wa0pBfjcqg
Cerevel Therapeutics said its Parkinson's disease drug improved symptom control in patients when tested as an add-on therapy, meeting the main goal in a late-stage study. https://t.co/vId87SMgST https://t.co/vId87SMgST
Cerevel's Parkinson's disease drug improves symptom control in late-stage trial https://t.co/CKhSL7TmAT https://t.co/sJ8Rz64TAV
Parkinson’s Disease Drug Tavapadon Significantly Improved Symptom Control, Cerevel Says https://t.co/AWP2E88Zp7 https://t.co/sNWUKDxedL
Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study https://t.co/jAhL6kBpoX by @NedPagliarulo $ABBV $CERE
$ABBV $CERE - very low expectation on the Parkinson's P3 readout - so ABBV get a good deal w/ CERE (assume no FTC issues and get the deal done) [of cuz, much of the value for CERE is with the M4 Schizo side - .. so those P2/P3s better work out.. ] jmho..
Cerevel drug for Parkinson’s improved symptom control in trial https://t.co/YyevJEgRoi
$CERE (+1.3% pre) $ABBV AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug - SA https://t.co/g3uOz4NDbn
"Tavapadon, a daily pill, works by partially activating the D1 and D5 dopamine receptors. Cerevel said this mechanism has the potential to achieve the right balance of dopamine signaling while avoiding overstimulation of the D2 & D3 dopamine receptors, which is thought to be… https://t.co/eu7AITS4cM
Cerevel Therapeutics reported that its investigational drug for Parkinson’s disease, tavapadon, improved motor symptom control when it was given as an add-on therapy to the well-known treatment levodopa in a late-stage clinical trial. https://t.co/ecuETPHTyg
Cerevel Therapeutics said on Thursday its Parkinson's disease drug met the main goal of a late-stage trial. https://t.co/a0MYYwsMgC https://t.co/a0MYYwsMgC
Good news for $ABBV here as a Cerevel Parkinson's drug looks to have scored in PhIII. That buyout slated to go through soon. From @MaxGelman and @AmberTongPW . Doesn't look like a game changer, but I could see Parkinson's patients adding it. https://t.co/XALOAJkQIl
Cerevel Therapeutics, which AbbVie is acquiring, said Thursday its drug tavapadon, taken with the common Parkinson's drug levodopa, showed positive results in controlling motor symptoms. https://t.co/OID54UtTSG
Cerevel notches Phase 3 Parkinson's win ahead of AbbVie transaction closing $CERE $ABBV https://t.co/8Nc4XQ81gR
Cerevel $CERE drug for Parkinson’s disease improved symptom control in trial $ABBV https://t.co/LZ8hygbcsF via @elaineywchen
$CERE Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease https://t.co/2Lv7X17NVZ